GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines, vaccines and consumer healthcare products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. The Consumer Healthcare business develops and markets products in Wellness, Oral health, Nutrition and Skin health categories. Its product portfolio includes Adartrel, Bexsero, Daraprim and Quinvaxem. Its brands include Panadol, abreva, polident and physiogel.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Pharmaceuticals - NEC
- Sub-Industry: N/A
- Symbol: NYSE:GSK
- CUSIP: N/A
- Web: www.gsk.com
- Market Cap: $100.45873 billion
- Outstanding Shares: 2,443,000,000
- 50 Day Moving Avg: $42.93
- 200 Day Moving Avg: $41.77
- 52 Week Range: $37.20 - $45.58
Sales & Book Value:
- Trailing P/E Ratio: 45.58
- Foreward P/E Ratio: 13.91
- P/E Growth: 1.16
- Annual Revenue: $38.07 billion
- Price / Sales: 2.61
- Book Value: $0.92 per share
- Price / Book: 44.29
- Annual Dividend: $1.94
- Dividend Yield: 4.8%
- EBIDTA: $9.57 billion
- Net Margins: 5.48%
- Return on Equity: 113.31%
- Return on Assets: 9.03%
- Debt-to-Equity Ratio: 2.61%
- Current Ratio: 0.89%
- Quick Ratio: 0.61%
- Average Volume: 2.77 million shs.
- Beta: 1.04
- Short Ratio: 1.71
Frequently Asked Questions for GlaxoSmithKline PLC (NYSE:GSK)
What is GlaxoSmithKline PLC's stock symbol?
GlaxoSmithKline PLC trades on the New York Stock Exchange (NYSE) under the ticker symbol "GSK."
How often does GlaxoSmithKline PLC pay dividends? What is the dividend yield for GlaxoSmithKline PLC?
GlaxoSmithKline PLC announced a quarterly dividend on Wednesday, July 26th. Investors of record on Friday, August 11th will be paid a dividend of $0.491 per share on Thursday, October 12th. This represents a $1.96 dividend on an annualized basis and a yield of 4.82%. The ex-dividend date of this dividend is Wednesday, August 9th. This is a positive change from GlaxoSmithKline PLC's previous quarterly dividend of $0.46. View GlaxoSmithKline PLC's Dividend History.
How were GlaxoSmithKline PLC's earnings last quarter?
GlaxoSmithKline PLC (NYSE:GSK) announced its earnings results on Wednesday, July, 26th. The company reported $0.70 EPS for the quarter, topping analysts' consensus estimates of $0.68 by $0.02. The business earned $9.36 billion during the quarter, compared to the consensus estimate of $9.52 billion. GlaxoSmithKline PLC had a net margin of 5.48% and a return on equity of 113.31%. View GlaxoSmithKline PLC's Earnings History.
Where is GlaxoSmithKline PLC's stock going? Where will GlaxoSmithKline PLC's stock price be in 2017?
18 equities research analysts have issued 1-year price targets for GlaxoSmithKline PLC's stock. Their forecasts range from $37.00 to $50.00. On average, they expect GlaxoSmithKline PLC's stock price to reach $45.67 in the next twelve months. View Analyst Ratings for GlaxoSmithKline PLC.
Who are some of GlaxoSmithKline PLC's key competitors?
Some companies that are related to GlaxoSmithKline PLC include Novartis AG (NVS), Pfizer (PFE), Merck & Company (MRK), Sanofi (SNY), Novo Nordisk A/S (NVO), Bristol-Myers Squibb Company (BMY), Eli Lilly and Company (LLY), Abbott Laboratories (ABT), Astrazeneca PLC (AZN), AstraZeneca plc (AZN), Shire PLC (SHP), Teva Pharmaceutical Industries Limited (TEVA), Dr. Reddy's Laboratories Ltd (RDY), Valeant Pharmaceuticals International (VRX), Patheon NV (PTHN), Taro Pharmaceutical Industries (TARO), Catalent (CTLT) and Akorn (AKRX).
Who are GlaxoSmithKline PLC's key executives?
GlaxoSmithKline PLC's management team includes the folowing people:
- Emma Walmsley, Chief Executive Officer - Designate, Executive Director
- Simon Dingemans, Chief Financial Officer, Executive Director
- Patrick Vallance, President - Pharmaceuticals R&D, Executive Director
- Roger Connor, President - Global Manufacturing & Supply
- Abbas Hussain, President - Global Pharmaceuticals
- Shah Abbas Hussain, President - Global Pharmaceuticals
- Luke Miels, President - Global Pharmaceuticals
- Daniel E Troy, Senior Vice President, General Counsel
- Claire Thomas, Senior Vice President - Human Resources
- Nick Hirons, Senior Vice President – Global Ethics and Compliance
Who owns GlaxoSmithKline PLC stock?
GlaxoSmithKline PLC's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Fisher Asset Management LLC (0.51%), Confluence Investment Management LLC (0.08%), RE Advisers Corp (0.08%), Hamlin Capital Management LLC (0.07%), Miller Howard Investments Inc. NY (0.07%) and Kornitzer Capital Management Inc. KS (0.05%). View Institutional Ownership Trends for GlaxoSmithKline PLC.
Who sold GlaxoSmithKline PLC stock? Who is selling GlaxoSmithKline PLC stock?
GlaxoSmithKline PLC's stock was sold by a variety of institutional investors in the last quarter, including Miller Howard Investments Inc. NY, US Bancorp DE, Jarislowsky Fraser Ltd, Kornitzer Capital Management Inc. KS, P.A.W. Capital Corp, Janney Capital Management LLC, Prospera Financial Services Inc and Atria Investments LLC. View Insider Buying and Selling for GlaxoSmithKline PLC.
Who bought GlaxoSmithKline PLC stock? Who is buying GlaxoSmithKline PLC stock?
GlaxoSmithKline PLC's stock was purchased by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, Confluence Investment Management LLC, Aperio Group LLC, GW&K Investment Management LLC, Bank of Montreal Can, John G Ullman & Associates Inc., Honkamp Krueger Financial Services Inc. and Beacon Financial Group. View Insider Buying and Selling for GlaxoSmithKline PLC.
How do I buy GlaxoSmithKline PLC stock?
Shares of GlaxoSmithKline PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is GlaxoSmithKline PLC's stock price today?
MarketBeat Community Rating for GlaxoSmithKline PLC (NYSE GSK)MarketBeat's community ratings are surveys of what our community members think about GlaxoSmithKline PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of GlaxoSmithKline PLC stock can currently be purchased for approximately $40.75.
Consensus Ratings for GlaxoSmithKline PLC (NYSE:GSK) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Sell Rating, 7 Hold Ratings, 10 Buy Ratings|
|Consensus Rating:||Buy (Score: 2.50)|
|Consensus Price Target: ||$45.67 (12.07% upside)|
Analysts' Ratings History for GlaxoSmithKline PLC (NYSE:GSK)
(Data available from 7/28/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|7/27/2017||Citigroup Inc.||Reiterated Rating||Neutral||Low|
|7/24/2017||J P Morgan Chase & Co||Reiterated Rating||Neutral||Low|
|5/26/2017||Berenberg Bank||Upgrade||Hold -> Buy||Low|
|4/6/2017||BNP Paribas||Lower Price Target||$37.00||Low|
|4/5/2017||Exane BNP Paribas||Upgrade||Underperform -> Neutral||Low|
|3/9/2017||Liberum Capital||Initiated Coverage||Buy -> Buy||Low|
|3/9/2017||Kepler Capital Markets||Initiated Coverage||Reduce -> Reduce||Low|
|3/7/2017||Barclays PLC||Initiated Coverage||Equal Weight||N/A|
|2/19/2017||Jefferies Group LLC||Reiterated Rating||Buy||N/A|
|2/9/2017||Deutsche Bank AG||Reiterated Rating||Neutral||N/A|
|12/27/2016||Goldman Sachs Group, Inc. (The)||Reiterated Rating||Buy||N/A|
|10/26/2016||Beaufort Securities||Reiterated Rating||Buy||N/A|
|9/23/2016||Piper Jaffray Companies||Initiated Coverage||Overweight||N/A|
|9/20/2016||Bank of America Corporation||Reiterated Rating||Buy||$50.00||N/A|
|9/12/2016||HSBC Holdings plc||Reiterated Rating||Buy||N/A|
|8/17/2016||Shore Capital||Reiterated Rating||Hold||N/A|
|8/12/2016||Argus||Boost Price Target||Buy||$48.00 -> $50.00||N/A|
|5/26/2016||Cowen and Company||Downgrade||Outperform -> Market Perform||N/A|
|5/5/2016||Oddo Securities||Upgrade||Reduce -> Buy||N/A|
|2/26/2016||Cantor Fitzgerald||Initiated Coverage||Hold||N/A|
|2/4/2016||Sanford C. Bernstein||Boost Price Target||Market Perform||$43.00 -> $45.00||N/A|
|1/27/2016||Bryan, Garnier & Co||Upgrade||Neutral -> Buy||N/A|
|12/21/2015||Leerink Swann||Reiterated Rating||Market Perform||$48.00||N/A|
|11/6/2015||Morgan Stanley||Reiterated Rating||Neutral||N/A|
|10/31/2015||Societe Generale||Reiterated Rating||Sell||N/A|
|10/20/2015||Credit Suisse Group||Upgrade||Underperform -> Neutral||N/A|
Earnings History for GlaxoSmithKline PLC (NYSE:GSK)Earnings History by Quarter for GlaxoSmithKline PLC (NYSE GSK)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|7/26/2017||6/30/2017||$0.68||$0.70||$9.52 billion||$9.36 billion||View||N/A|
|4/26/2017||3/31/2017||$0.62||$0.62||$9.09 billion||$9.23 billion||View||N/A|
|2/8/2017||12/31/2016||$0.57||$0.65||$9.21 billion||$9.43 billion||View||Listen|
|10/26/2016||Q316||$0.77||$0.83||$8.92 billion||$9.90 billion||View||Listen|
|10/28/2015||Q3||$0.60||$0.71||$6.07 billion||$6.13 billion||View||N/A|
|7/29/2015||Q215||$0.50||$0.53||$9.14 billion||$9.02 billion||View||N/A|
|5/6/2015||Q115||$0.55||$0.48||$8.55 billion||$8.51 billion||View||N/A|
|2/4/2015||Q414||$0.86||$0.82||$6.14 billion||$6.19 billion||View||N/A|
|10/22/2014||Q314||$0.79||$0.90||$9.76 billion||$9.12 billion||View||Listen|
|7/23/2014||Q114||$0.71||$0.65||$10.13 billion||$9.47 billion||View||N/A|
|4/30/2014||Q413||$0.72||$0.70||$10.36 billion||$9.44 billion||View||N/A|
|2/5/2014||Q4||$0.30||$0.30||$6.84 billion||$6.91 billion||View||N/A|
|10/23/2013||Q313||$0.31||$10.31 billion||$10.09 billion||View||N/A|
Earnings Estimates for GlaxoSmithKline PLC (NYSE:GSK)
2017 EPS Consensus Estimate: $2.89
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Current Dividend Information for GlaxoSmithKline PLC (NYSE:GSK)
|Dividend Growth:||-3.10% (3 Year Average)|
|Payout Ratio:||194.00% (Trailing 12 Months of Earnings) |
68.31% (Based on This Year's Estimates)
66.21% (Based on Next Year's Estimates)
Dividend History by Quarter for GlaxoSmithKline PLC (NYSE GSK)
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Insider Trading and Institutional Ownership History for GlaxoSmithKline PLC (NYSE:GSK)
Insider Ownership Percentage: 10.00%Insider Trades by Quarter for GlaxoSmithKline PLC (NYSE:GSK)
Institutional Ownership Percentage: 8.98%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|10/24/2016||Plc Glaxosmithkline||Major Shareholder||Buy||66,500||$14.00||$931,000.00|| |
Headline Trends for GlaxoSmithKline PLC (NYSE:GSK)
Latest Headlines for GlaxoSmithKline PLC (NYSE:GSK)
GlaxoSmithKline PLC (GSK) Chart for Friday, July, 28, 2017